SCHEMBL5517437

SCHEMBL5517437

CCCO/N=C/c1cc[c]cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.43
PPARA Q07869 3/20 0.43
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
FAAH O00519 2/20 0.33
MIF P14174 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
ACHE P22303 1/20 0.32
KDM4E B2RXH2 1/20 0.32
SRC P12931 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5517442 1.00 PPARG (0.43) PPARGPPARAKMT2AMEN1ALDH1A1
SCHEMBL6571767 0.89 PPARG (0.46) PPARGPPARAKMT2AMEN1FAAH
SCHEMBL5958034 0.89 PPARG (0.46) PPARGPPARAKMT2AMEN1FAAH
SCHEMBL5957891 0.88 PPARG (0.42) PPARGPPARAFAAHMIFHDAC1
SCHEMBL5957890 0.88 PPARG (0.42) PPARGPPARAFAAHMIFHDAC1
SCHEMBL6569130 0.86 PPARG (0.41) PPARGPPARAFAAHMIFHDAC1
SCHEMBL2903032 0.85 SMN1; SMN2 (0.38) KMT2AMEN1ALDH1A1SMN1; SMN2NPC1
SCHEMBL2903030 0.85 SMN1; SMN2 (0.38) KMT2AMEN1ALDH1A1SMN1; SMN2NPC1
SCHEMBL6569069 0.80 PPARG (0.40) PPARGPPARAKMT2AMEN1SMN1; SMN2
SCHEMBL6569064 0.80 PPARG (0.40) PPARGPPARAKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0463488-B2 O-Benzyl oxime ethers and fungicides containing them BASF AG (DE) 2004-04-21 EP claimed
US-20070082877-A1 Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof BAYER CORPSCIENCE AKTIENGESELLSCHAFT (DE) 2007-04-12 US disclosed
US-20060122065-A1 Amide compound and method of controlling plant disease with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-06-08 US disclosed
EP-1577290-A1 AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME Sumitomo Chemical Company, Limited (JP) 2005-09-21 EP disclosed
EP-0463488-B2 O-Benzyl oxime ethers and fungicides containing them BASF AG (DE) 2004-04-21 EP disclosed
US-RE37839-E1 O-benzyloxime ethers and crop protection agents containing these compounds BASF AKTIENGESELLSCHAFT (DE) 2002-09-10 US disclosed
US-6326399-B1 CONTROLLING INSECTS, ARACHNIDS, NEMATODES BASF AKTIENGESELLSCHAFT (DE) 2001-12-04 US disclosed
US-6316459-B1 O-benzyloxime ethers and crop protection agents containing these compounds BASF AG (DE) 2001-11-13 US disclosed
US-6211190-B1 Pyrimidine derivatives, process and intermediate products for their preparation and pesticides or fungicides containing these derivatives BASF AKTIENGESELLSCHAFT (DE) 2001-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122065-A1 Amide compound and method of controlling plant disease with the same CBR3, C5, CLN6 PPARG 1884/4885PPARA 1920/4885KMT2A 2654/4885
US-20070082877-A1 Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof FBL, Q6ZSR9, DDT PPARG 2497/4885PPARA 2960/4885KMT2A 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.